Aptose Biosciences Company Leadership
| APTO Stock | USD 0.19 0.01 5.56% |
Aptose Biosciences employs about 35 people. The company is managed by 8 executives with a total tenure of roughly 11 years, averaging almost 1.0 years of service per executive, having 4.38 employees per reported executive. Analysis of Aptose Biosciences' management performance can provide insight into the firm performance.
| William Rice Chairman Chairman, CEO and Pres |
Aptose |
Aptose Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (1.3629) % which means that it has lost $1.3629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9413) %, meaning that it created substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aptose Biosciences' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 18.53, though Return On Tangible Assets are likely to grow to (3.75). At this time, Aptose Biosciences' Non Current Assets Total are very stable compared to the past year. As of the 15th of December 2024, Other Current Assets is likely to grow to about 2.8 M, while Total Assets are likely to drop about 12.3 M.As of the 15th of December 2024, Common Stock Shares Outstanding is likely to grow to about 7.1 M, though Net Loss is likely to grow to (35.8 M).
Aptose Biosciences Workforce Comparison
Aptose Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,899. Aptose Biosciences claims roughly 35.0 in number of employees contributing just under 2% to equities under Health Care industry.
Aptose Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptose Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptose Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aptose Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptose Biosciences Notable Stakeholders
An Aptose Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aptose Biosciences often face trade-offs trying to please all of them. Aptose Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aptose Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Rice | Chairman, CEO and Pres | Profile | |
| Fletcher Payne | CFO, VP | Profile | |
| Brooks MBA | VP Controller | Profile | |
| Philippe Ledru | Senior Officer | Profile | |
| Janet CA | VP Fin | Profile | |
| Rafael MD | Senior Officer | Profile | |
| Roger BSc | Vice Operations | Profile | |
| Marc Wiles | Senior Affairs | Profile |
About Aptose Biosciences Management Performance
The success or failure of an entity such as Aptose Biosciences often depends on how effective the management is. Aptose Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aptose management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aptose management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.94) | (3.75) | |
| Return On Capital Employed | 22.96 | 24.11 | |
| Return On Assets | (3.94) | (3.75) | |
| Return On Equity | 17.65 | 18.53 |
Aptose Biosciences Workforce Analysis
Traditionally, organizations such as Aptose Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aptose Biosciences within its industry.Aptose Biosciences Manpower Efficiency
Return on Aptose Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 6.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.